NVSEF News and Press, Novartis Ag Basel Akt From 08/29/23

2023-08-29 07:45:20 ET The Centers for Medicare and Medicaid Services (CMS) announced on Tuesday the first 10 Medicare Part D drugs it selected for pricing negotiations, a provision introduced as part of last year's Inflation Reduction Act. The list includes Eliquis , a blood thinne...

2023-08-24 09:44:18 ET The Biden administration is expected to announce the first 10 drugs that will be subject to Medicare price negotiations on Tuesday before the markets open, Politico reported, citing people familiar with the plans. The move, introduced as part of last year ...

2023-08-24 02:20:26 ET Summary Bristol-Myers has a strong history of investment outperformance during equity bear markets and recessions. The company is uniquely undervalued, with a low 8x P/E and nearly 4% cash dividend yield. After a weak first half of 2023, shares may rebou...

2023-08-18 08:03:01 ET More on Novartis Novartis: Q2 Beats Expectations, But Still Pricey Novartis: Strong Growth And Continued Expansion For KISQALI Novartis Buys Chinook: M&A To Drive Future Growth Novartis and Ionis in pact for new cardiovascular thera...

2023-08-08 13:05:05 ET Summary Eli Lilly and Company's Q2 2023 earnings were boosted by strong sales growth of three key products in its pipeline: Verzenio, Jardiance, and Mounjaro. Verzenio, a breast cancer drug, saw significant sales growth due to its approval for multiple indic...

2023-08-07 17:44:22 ET Summary On July 20, Johnson & Johnson, the mastodon of the healthcare sector, released its financial results for the 2nd quarter of 2023. However, those results were overshadowed by a federal judge's decision to dismiss a JNJ subsidiary's bankruptcy fili...

2023-08-03 08:28:46 ET More on Ionis, Novartis, etc. Novartis: Q2 Beats Expectations, But Still Pricey Novartis: Strong Growth And Continued Expansion For KISQALI Ionis: Potential Advancement Into HAE Space Makes This A Must Watch Novartis Buys Chinook: M&...

2023-08-02 08:56:23 ET More on TG Therapeutics TG Therapeutics: The Hype Is Gone TG Therapeutics: Fairly Valued After Earnings Miss, EU Deal (Rating Upgrade) TG Therapeutics: Addressing The SC Ocrevus Concern TG Therapeutics falls as Roche succeeds in Phase 3...

2023-07-31 18:17:01 ET Summary Adlai Nortye Ltd. has filed to raise $115 million in a U.S. IPO, although the final figure may differ. The firm is a clinical stage biopharma developing immunotherapy treatments for solid tumor cancer conditions. Adlai Nortye is in Phase 3 trials...

2023-07-30 09:05:25 ET Summary Alnylam partnered Roche to develop and commercialize zilebesiran for the treatment of hypertension. Alnylam's share price has not benefited as the announcement was followed by the company revealing a very long development timeline for the candidate. ...